News ReleaseView printer-friendly version << Back
AcelRx Pharmaceuticals to Present at Jefferies 2015 Global Healthcare Conference
Jefferies 2015 Global Healthcare Conference
The Jefferies presentation will be webcast live and can be accessed through the Investors page at www.acelrx.com. For those not available to listen to the live broadcast, a replay will be archived for 90 days and available through the Investors page on www.acelrx.com.
ARX-04 delivers 30 mcg sufentanil, a high therapeutic index opioid, sublingually through a disposable, pre-filled, single-dose applicator. AcelRx has reported positive results from the pivotal Phase 3 SAP301 ambulatory surgery study, and has advanced ARX-04 into a study (SAP302) in emergency room patients. Zalviso delivers 15 mcg sufentanil sublingually through a non-invasive delivery route via a pre-programmed, patient-controlled analgesia device. In response to the New Drug Application (NDA) AcelRx submitted to the
For additional information about AcelRx's clinical programs, please visit www.acelrx.com.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/acelrx-pharmaceuticals-to-present-at-jefferies-2015-global-healthcare-conference-300175295.html
Timothy E. Morris, Chief Financial Officer, 650.216.3511, firstname.lastname@example.org; Brian Korb, The Trout Group LLC, 646.378.2923, email@example.com